VEGF inhibition and renal thrombotic microangiopathy.

By V. Eremina, J. A. Jefferson, J. Kowalewska, H. Hochster, M. Haas, J. Weisstuch, C. Richardson, Jeffrey B. Kopp, M. Kabir, Peter H. Backx and 5 more. New England Journal of Medicine, 2008

694 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/781a3106fdbf471ccf6bfba6458bc32785f37cb9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Helmut Baumgartner
2. Jeroen J. Bax
3. Jose Luis Zamorano
4. P. Lancellotti
5. Paulus Kirchhof
6. Gregory Y. H. Lip
7. S. Agewall
8. R. Asteggiano

Citations in the corpus

• 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines (2016, background): “9, respectively, under bevacizumab, sorafenib and sunitinib.(163,164) A summary of the incidence of hypertension reported in patients with cancer taking these drugs can be found in the appendix at the end of this document.”